Sharma Shubham, Sethuraman Gayathree, Kumari Khushboo
Public Health, Indian Institute of Public Health, Gandhinagar, IND.
Public Health, Triyog Ayurved Hospitals, Chennai, IND.
Cureus. 2024 Oct 15;16(10):e71532. doi: 10.7759/cureus.71532. eCollection 2024 Oct.
Amidst the multifaceted challenges posed by COVID-19, interest in complementary and alternative medicine (CAM) has risen. Chyawanprash (CP), an Ayurvedic formulation, is recognized for its multifunctional properties. This systematic review aims to evaluate its safety and effectiveness as a COVID-19 prophylactic. A literature search was conducted for articles published within the past three years from databases such as Cochrane Library, PubMed, and Google Scholar. A total of 1008 articles were identified, and 34 were included for full-text screening, resulting in five randomized controlled trials (RCTs) meeting the eligibility criteria. Meta-analysis was performed using a random effects model, with results represented in odds ratio (95% confidence intervals (CIs)), and publication bias presented through funnel plots. The five clinical trials conducted in India analyzed 153,343 participants. In the meta-analysis, the odds ratios for COVID-19-positive patients, COVID-19-positive in symptomatic patients, healthcare resource utilization (HCRU), and adverse events were 0.45 (95% CI 0.06-3.08, p = 0.41), 0.37 (95% CI 0.01-12.86, p = 0.58), 0.95 (95% CI 0.18-5.04, p = 0.95), and 0.94 (95% CI 0.63-1.40, p = 0.75) respectively. Notably, significant heterogeneity was observed among studies including both COVID-19-positive cases (I= 80%, p = 0.007) and symptomatic COVID-19 cases (I= 83%, p = 0.01), whereas non-significant zero heterogeneity was observed in HCRU (I= 0%, p = 0.74) and adverse events (I= 0%, p = 1.00). The meta-analysis reveals a trend in the efficacy of CP as prophylaxis for COVID-19 treatments. However, owing to high heterogeneity and bias, further research is recommended.
在新冠疫情带来的多方面挑战中，人们对补充和替代医学（CAM）的兴趣有所增加。阿育吠陀配方的 chyawanprash（CP）因其多功能特性而受到认可。本系统评价旨在评估其作为新冠预防药物的安全性和有效性。我们对Cochrane图书馆、PubMed和谷歌学术等数据库在过去三年内发表的文章进行了文献检索。共识别出1008篇文章，其中34篇纳入全文筛选，最终有5项随机对照试验（RCT）符合纳入标准。采用随机效应模型进行荟萃分析，结果以比值比（95%置信区间（CI））表示，通过漏斗图呈现发表偏倚。在印度进行的5项临床试验分析了153343名参与者。荟萃分析中，新冠阳性患者、有症状的新冠阳性患者、医疗资源利用（HCRU）和不良事件的比值比分别为0.45（95%CI 0.06 - 3.08，p = 0.41）、0.37（95%CI 0.01 - 12.86，p = 0.58）、0.95（95%CI 0.18 - 5.04，p = 0.95）和0.94（95%CI 0.63 - 1.40，p = 0.75）。值得注意的是，在包括新冠阳性病例（I = 80%，p = 0.007）和有症状的新冠病例（I = 83%，p = 0.01）的研究中观察到显著异质性，而在HCRU（I = 0%，p = 0.74）和不良事件（I = 0%，p = 1.00）中观察到非显著的零异质性。荟萃分析揭示了CP作为新冠治疗预防药物有效性的一种趋势。然而，由于高度异质性和偏倚，建议进一步研究。
